Yumi Hakozaki

Combination treatment with a PI3K/Akt/mTOR pathway inhibitor overcomes resistance to anti-HER2 therapy in PIK3CA-mutant HER2-positive breast cancer cells

Yumi Fujimoto, Tomoko Morita, Akihiro Ohashi et al. · Scientific Reports · 2020 · 89 citations · Full text

Medicine, Oncology, Pharmacology +15

TAS6417/CLN-081 Is a Pan-Mutation–Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant <i>EGFR</i> Mutations

Hibiki Udagawa, Shinichi Hasako, Akihiro Ohashi et al. · Molecular Cancer Research · 2019 · 72 citations · Full text

Medicine, Oncology, Pharmacology +15

Impacts of the STING‐IFNAR1‐STAT1‐IRF1 pathway on the cellular immune reaction induced by fractionated irradiation

Junyan Du, Shun‐Ichiro Kageyama, Riu Yamashita et al. · Cancer Science · 2022 · 19 citations · Full text

Medicine, Immunology, Oncology +17

CDC7 inhibition induces replication stress-mediated aneuploid cells with an inflammatory phenotype sensitizing tumors to immune checkpoint blockade

Tomoko Morita, Jie Yu, Yukie Kashima et al. · Nature Communications · 2023 · 18 citations · Full text

Medicine, Immunology, Oncology +17